Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
Data on the efficacy and tolerability of piribedil in Asians are scarce. Forty-nine Filipino PD patients with motor fluctuations were enrolled in an 8-week trial of piribedil of up to 150 mg/day. Mean improvement was 48% for the motor UPDRS scores (tremor showed greatest change), and 43% for activities of daily living. Mean daily levodopa dose decreased by 17%, and mean duration of effect of levodopa increased by 1.3 h (45%). Most common side effects were hallucinations (20%), dyskinesias (20%), dizziness (8%), and sleepiness (6%). This trial shows that piribedil is effective and well-tolerated by Asian patients with advanced PD at least with short-term use.
Evidente
Virgilio Gerald H
VG
Department of Neurology, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA. evidente.virgilio@mayo.edu
Esteban
Raymund P
RP
Domingo
Francis M
FM
Carbajal
Lourdjean O
LO
Parazo
Mercedita A
MA
D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D010891:Piribedil / Q000627:therapeutic use*; D011446:Prospective Studies; D018709:Statistics, Nonparametric
D007980:Levodopa; D010891:Piribedil